Welcome to our dedicated page for Biophytis SA SEC filings (Ticker: BPTSY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biophytis SA filings document its foreign private issuer reporting for an ADR linked to a clinical-stage biotechnology company focused on age-related diseases. The company files Form 6-K reports that furnish press releases, interim financial reporting, meeting results, and other information distributed by the French issuer.
The filing record addresses BIO101 program disclosures, sarcopenia and obesity development updates, strategic and co-development agreements, capital increases, warrants, convertible debt repayment, bond financing amendments, and shareholder governance matters. These disclosures also show how the company reports financing activity and program spending alongside its Euronext Growth Paris ordinary-share listing and OTC ADS program.
Biophytis SA (BPTSY) reports that recent financing actions have strengthened its cash position and extended its cash runway into the first quarter of 2027. Gross cash inflows of €3.7 million came mainly from the exercise of 2026 share warrants and drawdowns on a Hexagon bond facility, leading to cash of €3.0 million as of August 31, 2026 (pro forma, unaudited).
The company reduced financial debt by more than 30% via €1.4 million of debt-to-equity conversions, bringing financial debt down from €4.27 million at December 31, 2025 to €2.90 million at August 31, 2026. These transactions resulted in the issuance of tens of millions of new shares and an estimated total of about 240 million shares outstanding.
Biophytis plans to use available cash and existing financing instruments to finalize preparations for its Phase 2 OBA obesity study, expected to start in the first quarter of 2027, and to support a Hong Kong joint venture preparing a Phase 3 SARA sarcopenia study in China while funding operations into the same period.
Biophytis SA (BPTSY) outlines progress on its Hong Kong joint venture, Biophytis Biopharmaceutical Holding LTD, created to develop and commercialize BIO101 for sarcopenia in China, Japan, and South Korea. Partners are finalizing initial contributions, expected to be completed by end of September 2026, subject to administrative approvals.
Biophytis will contribute BIO101-related patents in China, Japan, and South Korea and sign a license through which the joint venture will pay single-digit royalties on future sales. Asian partners will fund the joint venture with up to $20 million over three years, including $10 million in the first year and an initial $3 million tranche concurrent with IP contribution and licensing.
Biophytis and its founders will hold 29% of the joint venture and the Asian consortium 71%, with a five-member board (three Biophytis-side, two partners). Funding is expected to cover most costs of the SARA-31 Phase 3 trial in sarcopenia, enrolling 942 patients across China, Japan, and Europe, targeting conditional marketing authorizations in Asia and the EU.
Biophytis SA reports that Brazil’s health authority ANVISA has approved initiation of the Phase 2 OBA clinical trial of BIO101 in obesity, adding Brazil to previously secured approvals in the United States and Europe. This confirms the company’s capacity to run a multi-regional development program.
The OBA study will enroll 164 obese and overweight patients already treated with GLP-1 therapies to assess whether BIO101 can preserve muscle strength, mobility, and reduce sarcopenia risk. The primary endpoint is improvement in lower-limb strength measured by the knee extension test.
The trial is part of an existing licensing agreement with Brazilian partner Blanver, under which Biophytis may receive up to 108 million euros in upfront and milestone payments, plus double-digit royalties on future net sales in Latin America. EMBRAPII is providing non-dilutive financial support, and the study is scheduled to begin in early 2027.
Biophytis SA published audited parent-company financial statements for 2025 and announced that trading in its shares on Euronext Growth Paris has resumed. The statements, prepared under French accounting rules, show a net loss of €8.2 million and negative shareholders’ equity of €8.8 million for the year.
Total financial debt and current liabilities amounted to €11.9 million as of 31 December 2025, down 5% versus 2024, mainly from a €1.7 million reduction in bond borrowings after financial restructuring. Operating expenses fell 17%, helping reduce the net loss from €9.4 million in 2024.
Cash and cash equivalents were €187 thousand at year-end. Based on refinancing completed in early 2026, current plans and the Hexagon bond facility, the company expects to finance operations only through 30 September 2026, creating significant uncertainty about its ability to continue as a going concern. The statutory auditors reported they were unable to express an unqualified opinion, citing going-concern uncertainties and the accounting treatment of certain capital transactions.
Biophytis SA reported provisional, unaudited 2025 results showing no revenue and a net loss of €7.8 million, an improvement from €9.4 million in 2024 as research, development and administrative costs declined and financial expenses fell sharply.
Cash and cash equivalents were €190 thousand as of December 31, 2025, versus €72 thousand a year earlier, while total financial debt and current liabilities stood at €12.5 million. Management states that current resources, recent refinancing and access to a Hexagon bond facility should finance operations only until September 30, 2026, creating a material uncertainty about the company’s ability to continue as a going concern.
The company highlights a memorandum of understanding with Asian partners to form a Hong Kong joint venture for BIO101 in sarcopenia, with up to US$20 million to be invested and a first US$3 million tranche expected after JV registration. Trading in Biophytis shares on Euronext Growth Paris has been suspended since June 15, 2026 due to delayed publication of 2025 audited accounts and is expected to resume once audited financial statements are released, planned by the end of July 2026.
Biophytis SA announced that trading of its shares on Euronext Growth Paris has been temporarily suspended. Euronext took this step because the company did not publish its annual financial report for the fiscal year ended December 31, 2025, on time due to an operational delay in preparing the financial statements.
The annual report will be released after the accounts are certified by the statutory auditors, which the company expects to occur by the end of July 2026. Trading is expected to resume once the annual financial report has been published, and Biophytis plans to inform the market of the specific resumption date.
Biophytis SA has officially registered its Hong Kong joint venture, Biophytis Biopharmaceutical Group Limited, a key step in its Asia strategy. The new entity will develop and commercialize BIO101, particularly for treating sarcopenia, and support clinical programs in Asian markets.
Operational closing will include the transfer of Biophytis’ intellectual property to the joint venture and a first investment tranche of $3 million from Asian partners. Total secured funding can reach up to $20 million over three years, enabling trial preparation, regulatory submissions, site openings in China and Japan, and team recruitment. The joint venture is expected to be operational starting in July 2026.
Biophytis S.A. has submitted the registration filing for its new joint venture in Hong Kong, Biophytis Biopharmaceutical Holding LTD, created with Asian partners including Ronghui Renhe Life Technology. The joint venture is designed to speed up development and commercialization of BIO101 for sarcopenia across Asian markets.
Biophytis will contribute patents and a license to develop and commercialize BIO101 in China, Japan and South Korea, while Asian partners will provide a total committed financing of $20 million, starting with an initial $3 million tranche. After the expected official registration and Closing, the venture plans to launch operations focused on preparing a Phase 3 clinical study of BIO101 in Asia, filing required regulatory applications, and building local teams.
Biophytis S.A. has amended its straight bond financing facility with Hexagon Capital Fund, converting it into a revolving structure capped at 2,000 bonds outstanding and reducing the annual interest rate from 12% to 10%.
The facility is described as a €2 million line, supporting Biophytis’ plan to finance a joint venture in Hong Kong and the Phase 3 study in sarcopenia, as well as preparation of its obesity program. Since February 2026, 800 bonds with a nominal value of €800,000 have been issued, largely repaid through share issuances and offset receivables, leaving drawing capacity of €1,700,000 under the bond facility.